Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Laboratory Corp. of America Holdings    LH

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Laboratory Corp. of America Holdings : LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/13/2012 | 10:05pm CET

Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of March 12, 2012 to September 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 7, 2012, in addition to the continued accrual of the original issue discount. Contingent cash interest, which the Company has determined to be approximately $1.50 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is August 26, 2012. The payment of contingent cash interest is expected to be made on September 11, 2012.

About LabCorp®

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.5 billion in 2011, over 31,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technology through its specialized labs and the LabCorp Specialty Testing Group: The Center for Molecular Biology and Pathology, National Genetics Institute, ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc., Monogram Biosciences, Inc., Colorado Coagulation, and Endocrine Sciences. LabCorp conducts clinical trials testing through its Esoterix Clinical Trials Services. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.

This press release contains forward-looking statements. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorp's financial results is included in the Company's Form 10-K for the year ended December 31, 2011, and subsequent SEC filings.

LabCorp
Stephen Anderson, 336-436-5274
www.labcorp.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LABORATORY CORP. OF AMERIC
06:44p LABORATORY OF AMERICA : Cority Enhances Clinical Testing Solution with LabCorp I..
11:51a LABORATORY OF AMERICA : LabCorp Announces New Expanded Use for PD-L1 Test with B..
11/15 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
11/15 LABORATORY OF AMERICA : LabCorp Announces New Expanded Use for PD-L1 Test with B..
11/15 LABORATORY OF AMERICA : LabCorp Earns 100 Percent on Human Rights Campaign Found..
11/15 LABORATORY OF AMERICA : LabCorp Receives 2017 Partnership Award from Be the Matc..
11/14 LABORATORY CORP. OF AMERICA HOLDINGS : Earnings Review and Free Research Report:..
11/13 LABORATORY OF AMERICA : LabCorp Receives 2017 Partnership Award from Be The Matc..
11/13 LABORATORY CORP OF AMERICA HOLDINGS : Regulation FD Disclosure (form 8-K)
11/13 LABORATORY OF AMERICA : LabCorp Earns 100 Percent on Human Rights Campaign Found..
More news
News from SeekingAlpha
11/15 LabCorp launches companion diagnostic for new Opdivo indications
11/07 Laboratory Corporation Of America (LH) Presents At Credit Suisse 26th Annual ..
10/27 LabCorp's (LH) CEO Dave King on Q3 2017 Results - Earnings Call Transcript
10/25 Laboratory Corporation of America beats by $0.07, beats on revenue
10/24 Notable earnings before Wednesday?s open
Financials ($)
Sales 2017 10 201 M
EBIT 2017 1 680 M
Net income 2017 788 M
Debt 2017 6 411 M
Yield 2017 -
P/E ratio 2017 19,88
P/E ratio 2018 17,65
EV / Sales 2017 2,14x
EV / Sales 2018 1,93x
Capitalization 15 469 M
Chart LABORATORY CORP. OF AMERIC
Duration : Period :
Laboratory Corp. of Americ Technical Analysis Chart | LH | US50540R4092 | 4-Traders
Technical analysis trends LABORATORY CORP. OF AMERIC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 173 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
David P. King Chairman, President & Chief Executive Officer
Glenn A. Eisenberg Chief Financial Officer, Treasurer & Executive VP
Mark Elliott Brecher Chief Medical Officer & Senior Vice President
Lance V. Berberian Chief Information Officer & Senior Vice President
Marcia T. Eisenberg Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
LABORATORY CORP. OF AMERICA HOLDINGS16.35%15 469
FRESENIUS MEDICAL CARE3.72%30 340
HCA HEALTHCARE INC1.23%27 444
QUEST DIAGNOSTICS INC-0.05%12 668
DAVITA INC-15.30%10 638
UNIVERSAL HEALTH SERVICES, INC.-9.97%9 341